Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16), Zacks reports. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. During the same quarter in the previous year, the business posted ($0.17) EPS.

Theravance Biopharma Stock Performance

Shares of TBPH traded down $0.13 during midday trading on Thursday, hitting $9.55. The company had a trading volume of 23,799 shares, compared to its average volume of 344,891. The company’s 50-day simple moving average is $8.36 and its 200-day simple moving average is $8.69. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.71. The firm has a market capitalization of $467.21 million, a P/E ratio of -9.58 and a beta of 0.25.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TBPH shares. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, TD Cowen reduced their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $13.75.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.90% of the stock is owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.